RecruitingNCT06941012
Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution
Studying Autosomal dominant multiple pterygium syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Casa di Cura IGEA
- Principal Investigator
- Marco Feligioni, PHDEBRI-European Brain Research Insitute
- Intervention
- Blood draw for the laboratory assessment(other)
- Enrollment
- 1200 target
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2025 – 2029
Study locations (4)
- Aristotle University of Thessaloniki, Thessaloniki, Greece
- Casa di Cura Igea, Milan, Mi, Italy
- Instytut Psychiatrii I Neurologii, Warsaw, Poland
- Asociacion Parkinson Madrid, Madrid, Spain
Collaborators
Asociación Parkinson Madrid · Aristotle University Of Thessaloniki · Institute of Psychiatry and Neurology, Warsaw · LINKCARE HEALTH SERVICES SL · ALMAWAVE SPA · European Brain Research Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06941012 on ClinicalTrials.govOther trials for Autosomal dominant multiple pterygium syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06949670Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseTianjin Medical University
- RECRUITINGPHASE3NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT05281003Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)Fudan University
- ACTIVE NOT RECRUITINGPHASE1NCT05382325A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Merck Sharp & Dohme LLC
- RECRUITINGNCT07533799The Swedish BioFINDER Sleep StudySkane University Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCAstraZeneca
- RECRUITINGPHASE1, PHASE2NCT04938817Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Merck Sharp & Dohme LLC
- RECRUITINGNCT04724941Prodromal Alpha-Synuclein Screening in Parkinson's Disease StudyUniversity Hospital Schleswig-Holstein
See all trials for Autosomal dominant multiple pterygium syndrome →